Health-Related Quality of Life Low in Younger Colorectal Cancer Survivors
January 18th 2021The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.
Read More
Second-Line Pembrolizumab Shows Continued OS and PFS Improvement in Advanced HCC
January 18th 2021In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.
Read More
Survival Benefit Maintained With Atezolizumab Plus Bevacizumab in Advanced HCC
January 17th 2021Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.
Read More
Infigratinib Promotes Clinical Activity in Patients With Chemo-Refractory, FGFR2+ Cholangiocarcinoma
January 17th 2021In a phase 2 clinical trial, the oral, FGFR1-3 selective tyrosine kinase inhibitor, infigratinib correlated with promising anticancer activity in addition to manageable safety as treatment of patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.
Read More
Ivosidenib Improves Overall Survival in Advanced IDH1+ Cholangiocarcinoma
January 17th 2021The final overall survival analysis of the phase 3 ClarIDHy trial demonstrated that treatment with ivosidenib tablets achieved a 21% reduction in the risk of death in patients with IDH1-mutant cholangiocarcinoma compared with placebo.
Read More
TAS-102 Shows OS Benefit With Bevacizumab in mCRC Ineligible for Intensive Therapy
January 17th 2021The frontline combination of trifluridine/tipiracil in combination with bevacizumab demonstrated an overall survival benefit compared with capecitabine and bevacizumab as treatment of patients with unresectable metastatic colorectal cancer who are not eligible for a standard chemotherapy regimen, resulting in a difference of almost 5 months, according to the final analysis of the phase 2 TASCO1 trial.
Read More
Step Counts Correlated With QoL With SM-88 in Metastatic Pancreatic Cancer
January 16th 2021Step counts appeared to correlate with self-reported quality of life during the first 2 weeks of treatment with SM-88 in patients with metastatic pancreatic cancer, the results of a preliminary exploratory analysis from part 2 of the phase 2/3 TYME-88-Panc trial showed.
Read More
Long-Term Benefit of Pembrolizumab in MSI-H/dMMR mCRC Seen in PFS2, HRQoL
January 16th 2021The use of pembrolizumab monotherapy upfront significantly improved progression-free survival while demonstrating superior safety, compared with chemotherapy, in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.
Read More
Frontline Bemarituzumab Doublet Prolongs Survival in Advanced FGFR2b+ Gastric/GEJ Cancer
January 16th 2021In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.
Read More
Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer
January 15th 2021Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer, according to data from the phase 3 JCOG 1109 trial that were virtually presented at the 2021 Gastrointestinal Cancers Symposium.
Read More
Lenvatinib/Pembrolizumab Deemed Safe and Effective in Select GI Cancers
January 15th 2021In multiple gastrointestinal tumor types, the combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile, according to data presented at the 2021 ASCO Gastrointestinal Cancers Symposium.
Read More
Anlotinib Improves PFS in RAS/BRAF Wildtype-Positive Metastatic Colorectal Cancer
January 15th 2021Treatment with the multi-target tyrosine kinase inhibitor anlotinib led to a significant improvement in progression-free survival along with a tolerable and manageable safety profile in Chinese patients with refractory metastatic colorectal cancer. according to results from the phase 3 ALTER0703 trial.
Read More
Nivolumab Shows QoL Improvement in Esophageal and Gastroesophageal Cancers
January 15th 2021Esophageal-specific and general quality of life was improved in patients with esophageal/gastroesophageal cancer who received nivolumab in the Checkmate 577 clinical trial, according to subgroup analysis data presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
Read More
Pembrolizumab/Trastuzumab Regimen Effective in Treating HER2-Positive Advanced Gastric, GEJ Cancer
January 15th 2021The addition of pembrolizumab and trastuzumab to the combination cisplatin plus capecitabine was able to effectively treat HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of PD-L1 expression in the phase 1b/2 PANTHERA trial.
Read More
Camrelizumab Combo Elicits Encouraging Efficacy in Second-Line Esophageal Squamous Cell Carcinoma
January 15th 2021Camrelizumab in combination with apatinib demonstrated encouraging clinical efficacy as a second-line treatment of patients with esophageal squamous cell carcinoma and demonstrated acceptable safety in a single-arm, open-label phase 2 clinical trial.
Read More
Pembrolizumab Plus Lanreotide Induces High Response Rates in GEP Neuroendocrine Tumors
January 15th 2021Roughly 40% of patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors treated with pembrolizumab in combination with lanreotide achieved stable disease, according to results from the phase 1b/2 PLANET clinical trial presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancer Symposium.
Read More
Safety of Pembrolizumab With Capecitabine and Bevacizumab Demonstrated in MSS mCRC
January 15th 2021Immunotherapy with pembrolizumab in combination with capecitabine-based chemotherapy and the VEGF inhibitor bevacizumab, appeared tolerable as treatment of patients with microsatellite stable metastatic colorectal cancer, showing a safety profile that was expected with the drug, results from a phase 2 study show.
Read More
ctDNA Biomarker for Responses, Outcomes Observed for High-Risk Patients With Early Breast Cancer
December 15th 2020Following neoadjuvant chemotherapy with or without pembrolizumab in patients with high-risk early-stage breast cancer, the presence of ctDNA was a biomarker for response and distant recurrence-free survival.
Read More
Tesetaxel Plus Capecitabine Combo Improves PFS in HR+ Metastatic Breast Cancer
December 15th 2020Treatment with tesetaxel plus a reduced dose of capecitabine improved progression-free survival in patients with HER2–, HR+ metastatic breast cancer compared with the FDA-approved dose of capecitabine alone.
Read More
iDFS Not Improved 1-Year of Added Palbociclib to Endocrine Therapy in HR+/HER2- Breast Cancer
December 12th 2020In the phase 3 PENELOPE-B clinical trial, adding 1 year of palbociclib to endocrine therapy did not demonstrate improvement in invasive disease-free survival in patients with hormone receptor–positive, HER2-negative breast cancer who are at high risk of relapse following neoadjuvant chemotherapy, according to results presented at the 2020 San Antonio Breast Cancer Symposium.
Read More
For patients with node-negative early breast cancer, RSClin, an intergration of the 21-gene expression assay and clinical pathologic features, provided more prognostic information compared with the 21-gene recurrence score or clinical pathologic features alone, as well as a more precise prediction of absolute chemotherapy benefit.
Read More
Antiematics and Loperamide Resolve GI AEs Related to Oral Paclitaxel Plus Encequidar in mBC
December 12th 2020Using 5- HT3 inhibitors and early intervention with loperamide was shown to manage gastrointestinal adverse events oral paclitaxel and encequidar in patients with metastatic breast cancer, according to a study presented during the San Antonio Breast Cancer Symposium.
Read More
Sacituzumab Govitecan Shows PFS Benefit for Patients With mTNBC and Brain Metastases
December 11th 2020Sacituzumab govitecan led to improvements in response rates and progression-free survival (PFS) compared with chemotherapy for patients with metastatic triple-negative breast cancer who had stable brain metastases in a subgroup analysis from the phase 3 ASCENT trial.
Read More